PHILADELPHIA, January 07, 2026--iECURE Receives FDA Regenerative Medicine Advanced Therapy Designation for ECUR-506 for ...
Archie was born with a rare condition and was treated in Glasgow Children's Hospital before being transferred to London to ...
Precision BioSciences évalue actuellement différents schémas posologiques, notamment des intervalles plus courts entre les doses, afin de déterminer l’approche optimale avant de passer à la phase ...
iECURE, Inc., a genome editing company focused on the development of variant-agnostic in vivo targeted gene insertion therapies for the treatment of liver disorders with significant unmet need, today ...
Little Archie, from Inverness, was diagnosed with Ornithine Transcarbamylase Deficiency, an extremely rare condition which ...
Stocks trading under $10 rarely come with the potential for life-changing gains, especially in today’s cautious market. In ...